Overview
Marginal zone lymphoma (MZL) is a heterogeneous B-cell non-Hodgkin lymphoma characterized by its origin in the marginal zones of lymphoid tissues, primarily affecting the spleen, lymph nodes, and mucosa-associated lymphoid tissue 1.Diagnosis
Imaging studies (CT, MRI) to assess organ involvement 1.
Bone marrow biopsy to evaluate for extranodal dissemination 1.
Flow cytometry and immunohistochemistry for immunophenotyping 1.
Histopathological examination of involved tissues for characteristic features 1.Management
First-line treatment: Observation for asymptomatic patients with low tumor burden 1.
Immunochemotherapy: Rituximab monotherapy or in combination with chemotherapy (e.g., CHOP regimen) for symptomatic or advanced disease 1.
Radiation therapy: Considered for localized disease or bulky lesions 1.
Targeted therapies: Limited evidence; ongoing research for specific molecular targets 1.Special Populations
Pregnancy: Management strategies are not detailed in the provided abstracts; individualized care based on disease stage and maternal health is recommended 1.
Pediatrics: Not covered in the reviewed studies 1.
Elderly: Treatment decisions should consider comorbidities and functional status; less intensive regimens may be appropriate 1.
Comorbidities: Tailor treatment based on patient's overall health; careful monitoring required 1.Key Recommendations
Standardize endpoint definitions and choices in clinical trials for MZL to improve comparability of results (Evidence: Expert opinion) 1.
Use rituximab as a cornerstone of treatment, either alone or in combination with chemotherapy, for symptomatic or advanced MZL (Evidence: Moderate) 1.
Individualize management strategies, particularly in special populations like pregnant women and the elderly, considering disease stage and patient-specific factors (Evidence: Expert opinion) 1.References
1 Bommier C, Ruggiu M, Monégier A, Zucca E, Thieblemont C, Lambert J. Systematic review reveals urgent need to homogenize endpoints choices and definitions in marginal zone lymphomas trials. Leukemia & lymphoma 2022. link